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Graft-versus-host disease (GVHD), in both its acute (aGVHD) and chronic (cGVHD) forms, remains a major
obstacle impeding successful allogeneic hematopoietic stem cell transplantation (allo-HSCT). T cells, in
particular pathogenic T helper (Th) 1 and Th17 subsets, are a driving force for the induction of GVHD. IL-12
and IL-23 cytokines share a common p40 subunit and play a critical role in driving Th1 differentiation and in
stabilizing the Th17 phenotype, respectively. In our current study, we hypothesized that p40 is an essential
cytokine in the development of GVHD. By using p40-deﬁcient mice, we found that both donor- and host-
derived p40 contribute to the development of aGVHD. Neutralization of p40 with an anti-p40 mAb inhibi-
ted Th1- and Th17-polarization in vitro. Furthermore, anti-p40 treatment reduced aGVHD severity while
preserving the graft-versus-leukemia (GVL) activity. Alleviation of aGVHD was associated with an increase of
Th2 differentiation and a decrease of Th1 and Th17 effector T cells in the GVHD target organs. In addition,
anti-p40 treatment attenuated the severity of sclerodermatous cGVHD. These results provide a strong
rationale that blockade of p40 may represent a promising therapeutic strategy in preventing and treating
aGVHD and cGVHD while sparing the GVL effect after allo-HSCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION features caused by alloreactive T and B cells [4]. In the
Allogeneic hematopoietic stem cell transplantation
(allo-HSCT) is the only curative option for many hemato-
poietic neoplastic diseases. However, its efﬁcacy is limited
by the occurrence of graft-versus-host disease (GVHD),
which remains the major cause of morbidity and mortality
in the recipients of allo-HSCT [1,2]. Generally, GVHD
attributes its detrimental effects to an immunological
attack on recipient parenchymal organs by donor patho-
genic cells transplanted in the graft [3]. According to
distinct pathophysiology and clinical manifestations, GVHD
can be divided into 2 forms: acute GVHD (aGVHD) and
chronic GVHD (cGVHD) [1]. Donor T cellemediated injuries
in the liver, skin, and gut are the main characteristics of
aGVHD [2,3]. cGVHD manifests itself with more extensive
organ involvement and many autoimmune and ﬁbroticdgments on page 1204.
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ty for Blood and Marrow Transplantation.clinic, many patients have an overlap syndrome in which
features of aGVHD and cGVHD appear together [4,5]. Thus,
ﬁnding shared therapeutic targets of aGVHD and cGVHD
could be a highly efﬁcient method to control GVHD and
increase the overall success of allo-HSCT.
T helper (Th) CD4 cells can differentiate into several
distinct subsets, such as Th1, Th2, Th17, and T regulatory
cells, depending on the signals encountered. Among these,
Th1 and Th17 are the major pathogenic subsets that
induce aGVHD and cGVHD [6-9]. Paradoxically, exacer-
bated aGVHD was observed in mice receiving IFNg/ or
IL-17A/ T cells [10,11]. This phenomenon occurs because
IFNg/ T cells produce more IL-17A, whereas IL-17A/ T
cells produce more IFNg [10,11]. These results indicate that
Th1 and Th17 lineages are mutually inhibitory and that
each alone is sufﬁcient to induce GVHD. Furthermore, our
recent work clearly demonstrates that it is necessary to
block both Th1 and Th17 lineages to control the
development of aGVHD [12].
Cytokines produced by antigen-presenting cells (APCs)
are critical factors in T cell activation and differentiation,
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driving Th1 development and stabilizing the Th17 pheno-
type, respectively [13]. IL-12 and IL-23 belong to the IL-12
family of cytokines and function as master regulators for
innate and adaptive immunity [14]. Both IL-12 and IL-23
are heterodimeric cytokines, which have a shared p40
subunit, paired with either an a chain p35 or p19,
respectively [13]. Ustekinumab is an anti-p40 mAb speciﬁc
for amino acids 1 to 88 that speciﬁcally blocks the inter-
action of p40 with the IL-12Rb1 chain in the IL-12 and
IL-23 receptors in human [15]. This mAb is approved by the
United States Food and Drug Administration for the
treatment of moderate-to-severe psoriasis and shows
impressive efﬁcacy in the clinic [15,16].
Increased p40 mRNA has been found in GVHD target
organs, which is relevant to the localized production of IFNg
after allogeneic bone marrow transplantation (allo-BMT)
[17]. In the current study, we hypothesized that the blockade
of p40 could alleviate GVHD by regulating the differentiation
and function of Th1 and Th17 cells after allo-BMT. Here, we
provide evidence that both donor- and host-derived p40
contribute to the development of aGVHD. Overall, neutral-
izing p40 efﬁcaciously reduces Th1 and Th17 polarization
and alleviates the severity of aGVHD and cGVHD while
preserving graft-versus-leukemia (GVL) activity.MATERIALS AND METHODS
Mice
C57BL/6 (B6; H-2b), B6.Ly5.1 (H-2b), BALB/c (H-2d), and FVB (H-2q) mice
were purchased from the National Cancer Institute/National Institute of
Health. C3.SW-H2b/SnJ (H-2b), B10.D2 (H-2d), and the founders of p40/
mice on B6 background mice were purchased from the Jackson Laboratory.
All animals were housed in the American Association for Laboratory Animal
Careeaccredited Animal Resource Center at Medical University of South
Carolina. Experiments were carried out under protocols approved by the
Institutional Animal Care and Use Committee at the Medical University of
South Carolina.Figure 1. Role of donor-derived p40 in aGVHD. BALB/c mice were lethally irradiated at
5  106 T cells) or p40/ graft frommice on B6 background. Recipient mice were mon
from 2 replicate experiments with total 10 to 12 mice per group. (C) Spleens were colle
of CD4, CD8, B220, and H2Kb (donor marker). Absolute numbers of CD4þ, CD8þ, or B22
cell function was measured by stimulating spleen cells with anti-CD3 or lipopolysacch
assay. Data shown as mean  1 SD. *P < .05, ***P < .001.Cell Staining and Flow Cytometric Analysis
Mononuclear cell isolation from recipient spleen and liver was
carried out as previously described [12]. Standard ﬂow cytometric surface
staining was used. For intracellular cytokine staining, cells were stimu-
lated with 50 ng/mL PMA (Sigma-Aldrich, St. Louis, MO), 500 ng/mL
ionomycin (Sigma-Aldrich), and .7 ml/mL Golgi Plug (BD Biosciences, San
Jose, CA), and incubated at 37C for 4 hours before staining as recom-
mended by the manufacturer. The ﬂow antibodies used were as follows:
CD4-V450 (clone RM4-5, BD), CD8-APC-Cy7 (clone 53-6.7, BD), B220-PE
(clone RA3-6B2, eBioscience, San Diego, CA), H2Kb-APC (clone AF6-
88.5.5.3, eBioscience), H2Kq-Alexa Fluor 647 (clone KH114, Biolegend,
San Diego, CA), CD45.1-FITC (clone A20, BD), IFNg-Percp-Cy5.5 (clone
XMG1.2, eBioscience), IL-4-PE (clone 11B11, BD), IL-5-PE (clone TRFK5,
eBioscience), IL-17-PE-Cy7 (clone TC11-18H10.1, Biolegend), CXCR3-
Biotin (clone CXCR3-173, eBioscience), PD-1-PE (clone J43, eBioscience),
CXCR5-PE-Cy7 (clone SPRCL5, eBioscience), Ly9.1-Biotin (clone 30C7, BD),
Streptavidin-PE-Cy7 (BD), and Streptavidin-APC-Cy7 (BD). Stained cells
were analyzed using Diva software, LSR II (BD Biosciences) and FlowJo
(TreeStar, Ashland, OR).
In Vitro Generation of Th1 and Th17 Cells
Splenocytes were isolated from normal B6 mice and were CD8/CD25
depleted using negative selection. CD8/CD25-depleted splenocytes were
cultured with IL-2 (2 ng/mL) or anti-CD3 (1 mg/mL) plus IL-12 (10 ng/mL),
IFNg (1000 U/mL), and anti-IL-4 (10 mg/mL) for Th1 generation. For Th17
generation, cells were stimulated with anti-CD3 (1 mg/mL) in the presence of
IL-6 (10 ng/mL), TGF-b (5 ng/mL), anti-IFNg (10 mg/mL), and anti-IL-4 (10 mg/
mL). Cells were cultured in a 24-well plate in the presence of isotype or anti-
p40 mAb at the concentrations indicated for 3 days and then tested for the
expression of intracellular IFNg and IL-17. Supernatant from the cell culture
was harvested, diluted 2 times, and then IFNg production was measured
using ELISA.
GVHD Models
T cells were puriﬁed from spleen and lymph node cells by negative
selection using magnetic beads as previously described [12]. T cell purity
was typically more than 95%. T celledepleted (TCD) bone marrow (BM)
was prepared by complement lysis, as previously described, and
transferred at 5  106/mouse [12]. B6/BALB/c (1  106 T cells) and
FVB/B6 (2  106 T cells) MHC-mismatched bone marrow trans-
plantation (BMT) models were used for aGVHD experiments. B10.D2
/BALB/c (5  106 splenocytes) MHC-matched, minor histocompatibility
antigen (MiHA)-mismatched BMT model was used for cGVHD700 to 750 cGy and underwent transplantation with WT graft (5  106 BM and
itored for survival (A) and body weight changes (B) over time. Data were pooled
cted from each survived recipient 80 days after BMT and stained for expression
0þ donor cells were calculated and presented in a per spleen basis. (D) T and B
aride (LPS) for 3 days. Proliferation was assessed using [3H]-TdR incorporation
Figure 2. Role of host-derived p40 in aGVHD. WT or p40/ B6 mice were lethally irradiated at 950 to 1000 cGy. These recipients then underwent transplantation
with 5  106/mouse TCD-BM alone or with 2  106/mouse of total T cells isolated from FVB donor mice. Recipient mice were monitored for survival (A) and body
weight changes (B) over time. Data were pooled from 3 replicate experiments with total 16 mice per group. Upon completion of the experiment on day 80, spleens
were collected from surviving recipients for cell counting and ﬂuorescent-activated cell sorter analysis. Percentages or absolute numbers of donor-derived (H2Kqþ)
CD4, CD8 T cells, and B cells were shown in BM alone recipients (C, D) and BM plus T cell groups (E, F). The data present 3 to 5 mice in each group from 1 of 3 replicate
experiments. *P < .05.
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with total body irradiation administered at 700 cGy for BALB/c < 23 g or
750 cGy for those  23 g of initial body weight and 950 cGy for B6 mice <
23 g or 1000 cGy for those  23 g using an X-RAD 320 X-ray Irradiator
(Precision X-ray Inc., North Branford, CT). Within 24 hours after total
body irradiation, recipient mice underwent transplantation with TCD-BM
alone or together with puriﬁed T cells or splenocytes. The recipient mice
in aGVHD experiments were monitored for body weight and survival
twice weekly. The recipient mice in cGVHD experiments were monitored
for survival and clinical signs, such as weight loss, posture, activity, fur
texture, and skin integrity weekly [18].
Leukemia/Lymphoma Models and Bioluminescent Imaging (BLI)
B6/BALB/c MHC-mismatched and C3.SW-H2b/SnJ/B6MHC-matched,
MiHA-mismatched BMT models were used to examine the GVL effects of
donor T cells. B6/BALB/c (1 106 T cells) recipients were injected with 2 
103 luciferase-transduced A20 B cell lymphoma cells, whereas C3.SW-H2b/
SnJ/B6 (3  106 CD44 T cells) recipients with 1  105 C1498 luciferase-
transduced acute myeloid leukemia cells at the time of BMT. The recipient
mice were monitored for body weight and survival twice weekly, and the
clinical score and tumor growth weremonitored weekly. Mice were injected
i.p. with luciferin (150 mg/kg) and then anesthetized with isoﬂurane gas
using Xenogen XGI Gas Anesthesia System. The BLI was performed by usingthe IVIS system (Xenogen, Waltham, MA). The imaging data were analyzed
using Living Image Software (Xenogen). The mortality caused by tumor
relapse or GVHD was distinguished by BLI signal indicative of tumor relapse
and weight loss indicative of GVHD.
Antibody Treatment In Vivo
Anti-p40 mAb (CNTO3913) and its isotype control (CNTO6601) were
kindly provided by Janssen Research and Development, LLC, Spring House,
PA. These mAbs were injected i.p. at 25 mg/kg body weight on day 0 and
then 12.5 mg/kg twice weekly for 4 weeks after BMT.
Statistics
The percentages of body weight change, percentages of cell types, ab-
solute numbers of cells, and clinical scores in wild type (WT) versus knock
out, or isotype versus anti-p40 treatment were compared using 2-tailed
student t-test. The log-rank test was used for survival analysis.
RESULTS
Donor- and Host-Derived p40 Contribute to aGVHD
Severity
To examine the role of p40 produced by donor cells
in mediating aGVHD, we performed an allo-BMT using
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and tested the effects of p40 deﬁciency on donor BM and T
cells in the development of aGVHD. The BALB/c recipients of
p40/ BM and T cells had signiﬁcantly improved survival
compared with those that received WT cells (P ¼ .046)
(Figure 1A), yet weight loss was similar (P ¼ .184)
(Figure 1B) between the 2 groups. Consistent with allevia-
tion of aGVHD, the recipients of the p40/ graft had
improved donor CD4 T and B cell reconstitution compared
with those recipients of WT graft (P ¼ .04 and .04, respec-
tively) (Figure 1C). Furthermore, the function of T and B cells
in the recipients of p40/ graft was signiﬁcantly improved
compared to those in the recipients of WT graft (P ¼ .03 and
.001, respectively) (Figure 1D). These results indicate that
donor-derived p40 contributes to the development of
aGVHD after allo-BMT.
Because p40 can be produced by either donor or host
APCs and host APCs are critical to inducing aGVHD [19,20],
we assessed the role of host-derived p40 on the develop-
ment of aGVHD. Host-derived p40 had little or no effect on
donor BM engraftment because WT and p40/ recipients
infused with BM alone had comparable outcomes
(Figure 2A,B) and similar CD4, CD8 T, and B cell reconsti-
tution 80 days after BMT (P ¼ .33, .78, and .32, respectively)
(Figure 2C,D). However, p40/ recipients that underwentFigure 3. Effect of anti-p40 mAb on T cell polarization in vitro. (A) CD8/CD25-deplete
isotype or anti-p40 mAb at the concentrations indicated for 3 days (details were desc
IFNg was measured by ELISA. The levels of IFNg were reﬂected by average OD415 in
splenocytes were cultured in Th1 conditions or Th17 conditions for 3 days. Cultur
intracellular IFNg and IL-17 on gated CD4þ cells (B, C). The data present 5 replicate wel
.001.transplantation with donor allogeneic T cells had signiﬁ-
cantly improved survival (P ¼ .015) (Figure 2A) and
increased donor B cell reconstitution (P ¼ .02)
(Figure 2E,F). These data suggest that host-derived p40
also signiﬁcantly contributes to the development of
aGVHD.Anti-p40 mAb Inhibits the Activity of IL-12 and IL-23 in T
Cell Polarization In Vitro
Using gene deletion (p40/ mice), the data presented
above indicate that IL-12/23p40 may be a valid therapeutic
target for the control of aGVHD. To translate these ﬁndings to
a more practical, therapeutic approach, we then focused our
attention on systemically neutralizing IL-12 and/or IL-23 p40
using an anti-p40 mAb. We ﬁrst tested whether anti-p40
mAb could block Th1 and Th17 polarization in vitro by
antagonizing the activity of IL-12 and IL-23. Indeed, anti-p40
mAb inhibited IFNg production by T cells that were
stimulated with IL-12 plus IL-2 or anti-CD3 under Th1
polarizing conditions in a dose-dependent manner (P ¼ .007
and .02, respectively) (Figure 3A). Anti-p40 treatment also
inhibited intracellular expression of IFNg and IL-17 in T cells
stimulated by IL-12 (Th1 condition) and IL-23 (Th17 condi-
tion), respectively (Figure 3B,C). These data indicate thatd splenocytes were cultured with IL-2 or anti-CD3 plus IL-12 in the presence of
ribed in the Material and Methods). Culture supernatants were harvested and
duplicate wells from 1 of 2 replicate experiments. (B, C) CD8/CD25-depleted
ed cells were harvested and stained for the expression of surface CD4 and
ls in each group from 1 of 2 replicate experiments. *P < .05, **P < .01 and ***P <
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polarization in vitro.
Neutralizing p40 Alleviates aGVHD
Because anti-p40mAb signiﬁcantly reduced Th1 and Th17
polarization in vitro, we further hypothesized that neutral-
izing p40 would attenuate aGVHD after allo-BMT. By using
the B6/BALB/c BMT model, we found that systemically
giving anti-p40 mAb signiﬁcantly improved recipient
outcomes as reﬂected by signiﬁcantly better survival and less
body weight loss compared to the control treatment (P ¼
.004 and .001, respectively) (Figure 4A,B). These data
demonstrate that systemic administration of anti-p40 mAb
to neutralize p40 is an effective way to attenuate aGVHD
severity after allo-BMT.
To further understand the mechanism by which neutral-
izing p40 reduces aGVHD severity in vivo, we investigated
how anti-p40 treatment affects donor T cell activation, dif-
ferentiation, and migration after allo-BMT. Treatment with
anti-p40 mAb had no impact on IFNg- or IL-17eproducing T
cells, but it signiﬁcantly increased IL-4/5eproducing CD4 T
cells in recipient spleens at 14 days after BMT (P ¼ .028)
(Figure 5A,C). However, anti-p40 treatment signiﬁcantly
reduced IFNg-producing CD4 and CD8 T cells in the recipient
liver, a major target organ of aGVHD (P ¼ .012 and .043,
respectively) (Figure 5B,D). In addition, neutralization of p40
also signiﬁcantly reduced the number of IL-17eproducing
CD8 T cells in the recipient livers (P ¼ .047) (Figure 5D).
Anti-p40 treatment had no impact on T regulatory cell
differentiation between the 2 groups (data not shown). Thus,
in murine models, neutralizing p40 promoted Th2 differen-
tiation while reducing IFNg and IL-17 production in GVHD
target organs after allo-BMT.
Because donor T cell migration to target organs is an
essential step for the development of aGVHD [21], we further
tested the migratory ability of donor T cells during p40
neutralization. As shown in Figure 5E, there were signiﬁ-
cantly fewer CD4 and CD8 donor T cells in recipient liver 14
days after anti-p40 treatment (P¼ .03 and .016, respectively).
Given CXCR3 is a key chemokine receptor modulating T cell
migration to the liver, we measured CXCR3 expression on
donor T cells and found that anti-p40 treatment signiﬁcantly
decreased CXCR3 expression on donor CD4, but not CD8, T
cells (P ¼ .004 and .933, respectively) (Figure 5F). These data
suggest that anti-p40 treatment inhibits donor T cell
migration into the liver partially through downregulation of
CXCR3 expression. A trend of reduced pathology scores in theFigure 4. Effect of neutralizing p40 on aGVHD development. BALB/c mice were letha
alone or together with total T cells at 1  106/mouse from WT B6 mice. Recipient m
on day 0 and then 12.5 mg/kg twice weekly for 4 weeks. Recipient survival (A) and
repeated experiments with 10 mice in each group. **P < .01.GVHD target organs, such as liver and gut, was observed in
the recipients receiving anti-p40 mAb, although the
difference did not reach statistical signiﬁcance at 14 day after
BMT (data not shown).
Neutralizing p40 Maintained T CelleMediated GVL
Activity after Allo-BMT
Preserving the GVL effect is of paramount importance
when BMT is used as immunotherapy for hematologic
malignances. Hence, we next asked whether neutralizing
p40 would maintain GVL activity while alleviating aGVHD.
Using a B6/BALB/c BMT model supplemented with A20 B
cell lymphoma cells, the recipients of BM alone plus A20 died
within 2 weeks because of tumor relapse, and anti-p40
treatment without T cell infusion had no impact on tumor
relapse (Figure 6A-C). The recipients transferred with addi-
tional donor T cells survived signiﬁcantly longer than those
receiving BM alone, illustrated by little or no tumor signal.
However, the majority of these recipients treated with the
isotype control died from GVHD, as reﬂected by substantial
weight loss and lack of BLI signal. We observed that anti-p40
treatment increased the rate and duration of recipient sur-
vival, although not signiﬁcantly, and resulted in a 50% long-
term survival of recipients without GVHD or tumor relapse
(Figure 6A-C).
Because MHC-matched, MiHA-mismatched BMT
models provide additional clinical relevance, we next
tested the effects of anti-p40 treatment on GVL activity by
using a C3.SW-H2b/SnJ/B6 BMT model with C1498 mu-
rine acute myeloid leukemia cells. The recipients of BM
alone had leukemic relapse and all mice were dead by day
40 after BMT (Figure 7A-C). The addition of donor T cells
prevented leukemia relapse regardless of the treatment,
and the mortality of recipients was essentially caused by
GVHD. However, anti-p40 treatment signiﬁcantly pro-
longed recipient survival 50 days after BMT (P ¼ .026)
(Figure 7A). Taken together, these data indicate that anti-
p40 treatment alleviated aGVHD and largely preserved
GVL activity after allogeneic BMT.
Neutralizing p40 Alleviates cGVHD
We next wanted to determine whether neutralizing p40
could attenuate cGVHD. Using an MHC-matched but MiHA-
mismatched B10.D2/BALB/c model of sclerodermatous
cGVHD, we found that anti-p40 treatment signiﬁcantly
alleviated the clinical manifestations in recipients at day 50
after BMT (P ¼ .036) (Figure 8A). In contrast to the 30%lly irradiated at 700 cGy and then transplanted with 5  106/mouse TCD-BM
ice were injected i.p. with isotype or anti-p40 mAb at 25 mg/kg body weight
body weight changes (B) were monitored over time. Data were pooled from 2
Figure 5. Effect of neutralizing p40 on donor T cell differentiation and migration. BALB/c mice were lethally irradiated at 700 cGy and then transplanted with 5  106/
mouse TCD-BM alone from Ly5.1 B6mice or togetherwith total Tcells at 1106/mouse from Ly5.2 B6mice. Recipientmicewere treatedwith isotype or anti-p40mAb as
described in the Material and Methods. Fourteen days after BMT, recipient spleens and livers were collected. Mononuclear cells were isolated for cell counting and
ﬂuorescent-activatedcell sorter staining. (A, B) The expressionof intracellular IFNg, IL-4/5, and IL-17 is shownongateddonorH2KbþLy5.1CD4þ cells from the spleen and
liver. Absolute numbers of IFNg, IL-4/5, and IL-17 positive donor CD4 or CD8 T cells were shown in the spleen (C) or liver (D). (E) Absolute numbers of donor pathogenic
H2KbþLy5.1CD4 or CD8 Tcells in recipient livers were shown. (F) Percentage of CXCR3þ cells are shown on gated donor CD4 or CD8 Tcells in recipient spleens. The data
are pooled from 2 replicate experiments with 10 mice in each group. *P < .05 and **P < .01.
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survived with anti-p40 treatment (P ¼ .06) (Figure 8B).
Consistent with the observed alleviation of cGVHD clinical
manifestations, neutralizing p40 signiﬁcantly increased
donor-derived CD4 and CD8 T cell, but not B cell, reconsti-
tution in the recipient spleens 60 days after BMT (P ¼ .03,
.036, and .143, respectively) (Figure 8C,D). In addition, thegeneration of follicular T helper (Tfh) cells, which are critical
for germinal center formation and cGVHD induction [22],
was inhibited by blocking p40 (P ¼ .014) as measured by
coexpression of CXCR5 and PD-1 (Figure 8C,D). These data
demonstrate that neutralizing p40 reduces the severity of
cGVHD and improves immune reconstitution by constraining
Tfh generation after allo-BMT.
Figure 6. Role of neutralizing p40 on the GVL activity in MHC-mismatched BMT. BALB/c mice were lethally irradiated and underwent transplantation with 5  106/
mouse TCD-BM alone or plus puriﬁed T cells fromWT B6 mice at 1 106/mouse. Recipient mice were also infused with 2  103 luciferase-transduced A20 cells at the
day of BMT. Recipient mice were treated with isotype or anti-p40 mAb as described in the Material and Methods. Recipients were monitored for survival (A) and body
weight change (B) for 60 days after transplantation. Tumor growth was monitored using BLI on the dates indicated (C). The data are pooled from 2 replicate ex-
periments with 10 mice in each group.
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The current study provides data to demonstrate that both
donor- and host-derived p40 contributes to the development
of aGVHD and that neutralization of p40 reduces aGVHD
severity while preserving GVL activity. Treatment with anti-
p40 mAb inhibits Th1 and Th17 polarization in vitro and
promotes Th2 differentiation in murine GVHD models. Anti-
p40 treatment also inhibits donor T cell migration into GVHD
target organs, such as the liver. In addition, anti-p40 treat-
ment improves recipient clinical manifestations of cGVHD.
Host APCs play a critical role in the initiation of aGVHD,
while donor APCs also contribute to the activation and dif-
ferentiation of donor allogeneic T cells [23,24], and thus to
the development of GVHD [25]. IL-12 and IL-23 are mainly
produced by activated APCs, such as dendritic cells and
macrophages [13]. Along with modulating T cell differentia-
tion, IL-12 and IL-23 also act in an autocrine manner to
enhance the ability of APCs to present antigens to T cells [14].
Our data illustrated that genetic deﬁciency of p40 in the
donor or host signiﬁcantly improved recipient survival after
allo-BMT (Figures 1,2), indicating that both host APC- and
donor APC-derived IL-12/23 promote GVHD development.
Consistent with this, we found that neutralization of p40
effectively inhibited Th1 and Th17 polarization in vitro
(Figure 3). In contrast, we were unable to demonstrate the
effectiveness of p40 neutralization with mAb treatment in
blocking Th1 or Th17 differentiation after allo-BMT(Figure 5). The potential explanation would be the
following: (1) the dose of anti-p40 tested may not be sufﬁ-
cient to block p40 in vivo or (2) other cytokines may
compensate for the function of IL-12 and IL-23 in the gen-
eration and maintenance of Th1 and Th17 subsets. However,
anti-p40 treatment increased Th2 differentiation and
decreased the numbers of Th1 and Th17 cells in recipient
liver in the B6/BALB/c model, which likely contributed to
the alleviation of GVHD. Our observation is also consistent
with a previous study that showed neutralizing IL-12 by anti-
IL-12 Ab could attenuate aGVHD by driving Th2 differentia-
tion in mouse models [26].
T cell migration into peripheral organs is required for the
induction of GVHD. We found that anti-p40 treatment
signiﬁcantly reduced donor T cells present in the liver, a key
aGVHD target organ, which likely contributed to the allevi-
ation of aGVHD (Figure 5). It is well accepted that the che-
mokine system plays an important role in facilitating donor T
cell migration to GVHD target organs. Among these, CXCR3
has been shown to play a pivotal role in Th1 migration [27].
In accordance with these observations, we found that the
expression of CXCR3 on donor CD4 T cells was signiﬁcantly
reduced with anti-p40 mAb treatment, possibly due to the
requirement of Th1 commitment to promote CXCR3
expression [27,28]. Comparable CXCR3 expression in CD8 T
cells was seen regardless of anti-p40 treatment, suggesting
that CD8 T cell trafﬁcking is likely less dependent on CXCR3
Figure 7. Role of neutralizing p40 on the GVL activity after MHC-matched and MiHA-mismatched BMT. B6 mice were lethally irradiated and underwent trans-
plantation with 5  106/mouse TCD-BM alone or with puriﬁed CD44 -depleted T cells from C3.SW-H2b/SnJ mice at 3  106/mouse. Recipient mice were also infused
with 1 105 luciferase-transduced C1498 cells at the day of BMT. Recipient mice were treated with isotype or anti-p40 mAb as described in the Material and Methods.
Recipients were monitored for survival (A) and body weight change (B) for 50 days after transplantation. Tumor growth was monitored using BLI on day 21 (C). The
data are pooled from 2 replicate experiments with 12 mice in each group. *P < .05.
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anti-CXCR3 treatment reduced CD4 but not CD8 T cell inﬁl-
tration in the central nervous system in response to virus
infection [28]. However, there is another explanation that is
relevant to the GVHD model used. In B6 to BALB/c model,
GVHD is induced in a CD4-dependent manner, so we are
more likely to see differences in CD4 T cells. Whereas in
MiHA-mismatched C3.SW-H2b/SnJ to B6 model used in
Figure 5, GVHD is driven predominately by CD8 T cells. Thus,
it is possible that CXCR3 may differentially be expressed on
CD4 versus CD8 donor T cells in different models, which
might be responsible for the distinct effects of anti-p40 on
the migration of CD4 versus CD8 T cells.
Although signiﬁcantly attenuated aGVHD was seen when
blocking p40, the efﬁcacy of preventing aGVHD was not as
potent as was observed in our previous study with T-bet and
RORgt blockade [12]. The moderate alleviatory effect of anti-
p40 treatment on aGVHD could be due to the insufﬁcient
treatment dose and compensatory cytokine mechanisms
in vivo. In addition, p40 has also been shown to be a minor
regulator of inﬂammatory responses, suggesting that blockade
of p40 reduces IL-12 and IL-23 inﬂammatory cytokines but
simultaneously decreases the small regulatory effect of p40.
The p40 subunit is promiscuously expressed,whereas p35 and
p19 are only secreted as part of the heterodimer when p40 is
also produced by the same cells. As a result, p40 is often
secreted in larger quantities than p35 and p19 [13,14,29]. In
mice, free p40 can form homodimers or present as free
monomers, both of which have been shown to be naturalinhibitors of IL-12 [14,29-31]. This could explain the potent
effect of anti-p40 in polarizing conditions in vitro yet only
moderate effects in vivo in regard to blockade of Th1/Th17
differentiation. The potentially inhibitory roles of p40 homo-
dimers or monomers may also explain why targeting p19
seems more effective than targeting p40 to block the function
of IL-23 in the prevention of GVHD reported by others [32].
However, it is worth noting that homodimers and
monomeric p40 have not been found in humans, indicating
neutralization of p40 could possibly be more effective in
human diseases [14]. Indeed, our colleagues reported that
ustekinumab treatment of 1 patient with advanced, re-
fractory GVHD showed a brief clinical remission accompa-
nied by a decrease in IFNg production and an increase in IL-4
secretion by whole blood cells stimulated ex vivo with PMA/
ionomycin [33]. In addition, ustekinumab has been found to
be effective in several Th1/Th17-mediated human diseases,
although the shift toward Th2 differentiation has not been
observed, such as in psoriasis [15,34-36].
Of clinical importance, we assessed the T cellemediated
GVL activity upon neutralization of p40 in 2 preclinical BMT
models. When compared with BM alone, additional T cells
mediated robust antitumor effect regardless of anti-p40 or
isotype treatment (Figures 6,7), indicating that anti-p40
treatment largely preserved GVL activity. The preserved
GVL effect could be attributed to the maintained total
donor T cells (data not shown) and the numbers of IFNg-
producing donor T cells (Figure 5C) in recipient spleens after
anti-p40 treatment. Furthermore, a previous study has
Figure 8. Effect of neutralizing p40 on cGVHD. BALB/c mice were lethally irradiated and transplanted with 5  106/mouse TCD-BM alone or plus 5  106/mouse
splenocytes from B10.D2 donors. Recipient mice were treated with isotype or anti-p40 mAb as described in the Material and Methods. Recipients were monitored for
clinical manifestations (A) and survival (B). Sixty days after transplantation, recipient spleens were harvested and subjected to ﬂow staining for the expression of
Ly9.1 (recipient marker), CD4, CD8, B220, CXCR5, and PD-1. The representative ﬂow ﬁgures (C) and statistic bar graph (D) are shown. The data are pooled from 2
replicate experiments with 10 mice in each group. *P < .05.
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lymphocyte (CTL) function of CD8 T cells in vivo [37]. Taken
together, we concluded that inhibition of p40 attenuates
GVHD while sparing GVL activity after allo-BMT.
Considering that both Th1 and Th17 subsets contribute to
the development of cGVHD, we evaluated the effect of
neutralizing p40 on the developmentof cGVHD.We found that
anti-p40 treatment signiﬁcantly improved the clinical mani-
festations and immune reconstitution without GVHD related
mortality (Figure 8). IL-12 stimulation is critical for dendritic
cellemediated priming of naïve CD4 T cell into Tfh [38], and
subjects deﬁcient for IL-12Rb1, a receptor for p40, displayed
reduced circulatingTfh,memoryB cells and impaired germinal
center formation [39]. Consistent with this, we found that Tfh
generation was reduced with anti-p40 mAb treatment, which
possibly contributed to the reduced severity of cGVHD. The
current study agrees with a recent report that anti-p40 treat-
ment attenuates cGVHD in mice [40].
We illustrate that blocking IL-12/23p40 attenuates
cGVHD. Paradoxically, a previous study shows exogenous IL-
12 administration reduces the severity of cGVHD in a sys-
temic lupus erythematosus (SLE) model [41], inwhich a large
numbers of splenocytes from DBA/2 donors were transferred
into nonirradiated B6D2F1 recipients. There are several dif-
ferences in these 2 models: (1) the pathophysiology of the
SLE cGVHD model is characterized by B cell hyperactivation,
as well as autoantibody and immune complexemediated
glomerulonephritis, in which Th2 cells are the major path-
ogenic T cells contributing to allo-reactive B cell activation.The mechanism of reducing cGVHD by administration of IL-
12 in that study was likely because that IL-12 reduced Th2-
differentiation and further inhibited the pathogenesis of
allo-reactive B cells. On the other hand, the sclerodermatous
cGVHD model is characterized by ﬁbrosis in target organs,
which is predominately mediated by activated macrophages
and Th1/Th17. In the current study, we demonstrate that
blocking IL-12/23p40 reduces sclerodermatous cGVHD,
which is consistent with the recent publish by Okamoto, et al
[40]; (2) the preconditioning in the 2 cGVHD models are
different. The recipients in the SLE model did not receive any
irradiation before transplantation, which may affect the
contribution of IL-12 in the development of cGVHD; (3) IL-12
has been found to have a paradoxical role in the develop-
ment of GVHD [42,43]. A single injection of IL-12 on the day
of BMT inhibits aGVHD through Fas-mediated reduction of
donor T cell activation and expansion. The dose and timing of
IL-12 administration was critical for the protective effect, yet
only a low dose of IL-12 was protective and administration 1
hour before BMT was the most efﬁcacious; and (4) more
importantly, we targeted IL-12 and IL-23 in combination
rather than IL-12 alone. In short, the precise mechanisms
that account for the discrepancy from the work by Okubo
et al. [41] and the current work in the context of neutrali-
zation are not known and desirable for further investigation.
In conclusion, our study provides strong evidence that both
donor- and host-derived p40 are required for the development
of GVHD.Ustekinumabhas been approved for the treatment of
moderate-to-severe psoriasis, and in a phase 2B trial, adults
Y. Wu et al. / Biol Blood Marrow Transplant 21 (2015) 1195e12041204with moderate-to-severe Crohn’s disease resistant to anti-
tumor necrosis factor treatment showed an increased rate of
response to ustekinumab [44]. Our current work provides ev-
idence to support evaluation of p40 blockade as a potential
therapeutic target for the prevention and/or treatment of
GVHD while sparing the GVL effect after allo-HSCT.
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